Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on July 21, 2021. The filing discloses material information regarding a financing event involving Surface Ophthalmics, Inc. ("Surface"), a portfolio company in which Harrow holds an equity stake.
Key Financial Metrics
The filing does not provide Harrow Health's consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. The financial data disclosed pertains exclusively to Surface Ophthalmics, Inc.:
- Surface Financing Proceeds: Approximately $25,000,000 (gross) from a private placement of preferred stock.
- Surface Share Price: $4.50 per share.
- Harrow's Surface Stake: 3,500,000 shares of Surface common stock.
- Harrow's Royalty Rights: Mid-single digit royalty on net sales of SURF-100, SURF-200, and SURF-201.
Material Changes
The primary material change reported is the successful capital raise by Surface Ophthalmics. The proceeds are designated to complete ongoing Phase II clinical studies for SURF-100 and SURF-200 and to expand the Surface leadership team. This event may impact the valuation of Harrow's investment in Surface.
Outlook, Risks, and Management Commentary
Management commentary is limited to the description of the Surface press release. The filing notes that the use of proceeds is expected to advance clinical development. No specific risks, contingencies, or forward-looking guidance regarding Harrow Health's own operations are detailed in this specific 8-K filing.
Investor Verification Checklist
- Verify the full text of the Surface Ophthalmics press release (Exhibit 99.1) for details on investor participation and dilution.
- Confirm the current status of Phase II clinical studies for SURF-100 and SURF-200.
- Review Harrow's most recent 10-K or 10-Q to determine the carrying value of the Surface investment on Harrow's balance sheet.
- Assess the potential impact of the "mid-single digit" royalty rights on future revenue streams.